By Dr Clifford Gross, CEO of Tekcapital

In the rapidly evolving world of healthcare technology, few segments have generated as much attention in recent years as the portable oxygen concentrator (POC) market. Driven by aging populations, the rising incidence of chronic obstructive pulmonary disease (COPD) and other respiratory ailments, and a worldwide focus on at-home medical devices, POCs are well on their way to becoming indispensable tools for improving patient independence and quality of life. According to a report by OpenPR[1], the broader respiratory care market is projected to grow significantly by 2025, underscoring the far-reaching implications of portable oxygen solutions in supporting this surging demand. Indeed, from high-tech breakthroughs to increasing acceptance by insurers, the POC market is shedding its niche status and quickly taking center stage—particularly in the United States, the United Kingdom, and beyond.

Below is an expanded look at the projected trajectory for portable oxygen concentrators worldwide, drawing on additional data from the World Health Organization (WHO), plus a review of leading players—including Inogen and Belluscura—to illustrate the dynamic competition in this space. We also discuss emerging technologies, particularly Belluscura’s modular platform designed to future-proof patient care. Finally, we consider the financial potential of both new and established market contenders.

The Global Market Landscape and WHO Data

Although oxygen concentrators have existed for decades, recent technological leaps have propelled portable units into the healthcare spotlight. According to multiple public sources, the respiratory care market is estimated to be valued at USD 28.55 Billion in 2025 and is expected to reach USD 55.67 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 10.0% from 2025 to 2032.

The global portable oxygen concentrators (POC) market size was valued at USD 1.9 Billion in 2024. Looking forward, IMARC Group[2] estimates the market to reach USD 3.5 Billion by 2033, exhibiting a CAGR of 6.97% from 2025-2033. North America currently dominates the market, holding a significant market share of over 38.9% in 2024. The major factors driving the market are the rising cases of respiratory diseases such as chronic obstructive pulmonary disease, asthma, and cystic fibrosis, rising geriatric population and growing affinity for home-based medical treatment.

Crucially, the World Health Organization (WHO)[3] highlights the growing need for respiratory care solutions. COPD, which remains a prime driver of POC demand. COPD is the fourth leading cause of death worldwide, causing 3.5 million deaths in 2021, approximately 5% of all global deaths. Nearly 90% of COPD deaths in those under 70 years of age occur in low- and middle-income countries (LMIC). COPD is the eighth leading cause of poor health worldwide (measured by disability-adjusted life years). WHO data also indicates that over 250 million individuals globally suffer from some form of COPD, with a disproportionately high burden in low- and middle-income countries. These figures emphasize the global scale of respiratory ailments and suggest an ever-expanding market for devices that can manage chronic breathing conditions effectively.

Several factors explain this surge in demand:

1. Demographic Shifts: A rapidly aging global population, especially in industrialized nations, has driven up the number of patients with chronic respiratory conditions.
2. Home Healthcare Evolution: Healthcare systems worldwide are under pressure to reduce costs and limit hospital stays, resulting in increased adoption of home-based treatments.
3. Technological Refinements: Improvements in battery life, noise reduction, and unit size have made POCs lighter, quieter, and more energy-efficient, boosting their appeal to both patients and caregivers.

On the policy front, governments have also recognized the importance of accessible oxygen therapy. Since the COVID-19 pandemic, respiratory health infrastructure has garnered renewed attention, and insurers in many countries are offering broader reimbursements for portable oxygen devices. This climate—alongside persistent demand from a fast-growing patient base—sets the stage for continued growth.

A Few Global Players and the U.S. Market

In addition to Inogen (market leader) and Belluscura (leading innovator in the POC space), other notable portable oxygen concentrator manufacturers play a substantial role including:

• Philips Respironics: Known for its extensive range of respiratory care devices, Philips Respironics offers POCs like the SimplyGo and SimplyGo Mini. These devices feature user-friendly interfaces and relatively streamlined designs, appealing to patients looking for reliable technology backed by a global healthcare brand.
• ResMed: Primarily recognized for its sleep apnea and ventilation products, ResMed has also made inroads into the portable oxygen sphere, aiming to integrate oxygen delivery with its broader respiratory solutions.
• CAIRE Inc. (a division of Chart Industries): With a history in industrial and medical gases, CAIRE Inc. produces several portable concentrators, including the FreeStyle line, praised for its lightweight design and ease of use.
• Drive DeVilbiss Healthcare: Offering multiple models, Drive DeVilbiss has leveraged its extensive distribution network to expand POC sales worldwide.
• O2 Concepts: Known for innovative devices and robust battery life, O2 Concepts focuses on delivering higher flows in smaller packages.

The U.S. Market—A Hotbed of Innovation

Among these players, the United States stands out for its rapid adoption of POCs, propelled by:

1. Demographics: The large and fast-growing elderly population—often referred to as the “Silver Tsunami”—drives significant demand for COPD and respiratory aid solutions.
2. Homecare Shift: Healthcare systems encourage transitioning treatments from hospitals to the home, where POCs can replace bulky oxygen tanks and improve patient quality of life.
3. Innovation Ecosystem: Companies such as Inogen have invested heavily in research and development, pushing POC technology forward while also focusing on patient-friendly designs.

Inogen’s Role in the U.S. Market

Widely credited with popularizing portable oxygen therapy, Inogen posted revenue exceeding USD 361 million in 2022—a testament to its brand recognition, direct-to-consumer model, and growing acceptance among clinicians. Inogen’s user-focused approach, emphasizing easy-to-carry devices with extended battery life, has sharpened competition among rivals seeking a share of the lucrative U.S. POC sector. Many analysts anticipate that as insurance reimbursement policies expand and telemedicine further integrates respiratory care, Inogen’s sales and market penetration will continue to rise, maintaining its position as a formidable market leader.

The U.K. Market—Adoption and Growth Potential

Across the Atlantic, the United Kingdom offers another compelling narrative for POC adoption. With an aging population and a similarly high prevalence of COPD and other respiratory diseases, the UK’s National Health Service (NHS) is steadily incorporating portable oxygen therapy into community and domiciliary care. However, accessing the UK market often involves navigating different procurement procedures and evidentiary hurdles:

1. Cost-Effectiveness: NHS decision-makers prioritize solutions that lower hospital admissions and overall healthcare spending.
2. Clinical Validation: POC manufacturers must demonstrate improved patient outcomes—such as reduced exacerbations of COPD and better adherence to therapy protocols—to secure wide-scale adoption.
3. Systemic Pressures: The pandemic highlighted the importance of respiratory infrastructure and remote patient monitoring, driving renewed interest in portable solutions.

Market Projections

Despite these stricter adoption criteria, analysts predict POC usage in the UK to rise at a CAGR of 6% to 8% through 2026, mirroring broader European trends. The introduction of integrated care systems and increased telehealth capabilities within the NHS likely will open more avenues for portable oxygen devices to become part of standard homecare protocols.

Belluscura’s Modular Approach—A Potential Game-Changer

While Inogen retains a significant share of the spotlight, Belluscura is attracting growing attention with its modular POC design. This concept addresses a common challenge in respiratory therapy: as conditions like COPD advance, patients often need higher-flow oxygen, which traditionally meant purchasing a new device.

Belluscura’s Key Advantage

By allowing users to switch filter cartridges (or modules) in response to evolving oxygen needs, Belluscura’s devices deliver several potential benefits:

1. Future-Proofing and Cost Savings: Rather than investing in multiple concentrators over time, patients can upgrade modules to meet increasing needs, saving money in the long run.
2. Scalability: Healthcare providers can match therapy more precisely to individual patients, potentially reducing over-delivery or under-delivery of oxygen.
3. Enhanced Portability: Patients who initially require only lower-flow oxygen can use a lighter device—no larger than a standard portable unit—and then scale up without having to purchase an entirely new system.

In press releases and investor communications, Belluscura emphasizes “disruptive innovation,” noting that modular design could eventually become a standard expectation across the industry. If clinical data confirms that this flexibility reduces hospitalizations, improves compliance, and delivers cost benefits to insurers, Belluscura could see accelerating market adoption.

Future Value and Outlook for Industry Leaders

With multiple drivers at play—demographic shifts, government policies, healthcare cost pressures, and technology breakthroughs—analysts forecast sustained growth for the portable oxygen concentrator market over the next decade. The anticipated global increase in COPD cases, highlighted by the WHO, underscores the critical role that advanced respiratory care devices will play in patient wellness.

Inogen’s Future Value
Despite rising competition, Inogen’s established brand, distribution channels, and pipeline of R&D projects position it for continued success. Some industry observers predict Inogen’s valuation could climb at an annual rate of 10% to 15% over the next five years, contingent on maintaining U.S. market share and broadening its international reach. Changes in government reimbursements and regulatory frameworks may influence these projections, but Inogen appears poised to capitalize on a robust and expanding market.

Belluscura’s Future Value
As a newer entrant focused on innovative design, Belluscura has generated considerable interest—especially among those looking for devices that address changing patient needs over time. Interestingly, whilst the smallest in terms of revenue of all the POC companies covered, it has the largest innovation index due to its modular design, battery life, low-weight and quiet performance. If the company’s modular concept gains traction and clears major regulatory and reimbursement hurdles in other jurisdictions as it has done in the US and China, we think it could see annual valuation growth of 20% or more in the medium term. Much will depend on successful commercialization strategies, partnerships, and clinical validation demonstrating that Belluscura’s platforms meaningfully reduce costs and improve patient quality of life.

Note: Innovation Index Methodology: Calculated based on subjective weighting of factors including R&D investment, technological breakthroughs, patent filings, product design innovation, and market disruptiveness as interpreted from the source document. Scale of 0-100.

The Competitive Landscape and Concluding Thoughts

With Philips Respironics, ResMed, CAIRE Inc., Drive DeVilbiss Healthcare, and O2 Concepts also pursuing advancements in POC technology, the market is awash with innovation. Each manufacturer brings unique strengths—be it global reach, specialized engineering expertise, or broad product portfolios that span multiple respiratory segments. Ultimately, patients stand to benefit from the increasingly diverse range of products, which allow them to tailor their oxygen therapy more closely to their lifestyles.

Global Prospects
Market observers agree that we are entering a golden era for POCs. Aging populations, shifting healthcare models, and the WHO-documented surge in COPD prevalence combine to create fertile ground for sustained demand. Meanwhile, research and development in lightweight, high-efficiency concentrators—alongside new financing and reimbursement models—suggest that portable oxygen therapy will remain a dynamic and fast-growing category.

Looking Ahead
The winners in this sector will likely be those companies that balance innovation with real-world data demonstrating clinical efficacy and cost-effectiveness. Whether through modular design or by enhancing portability, battery life, and connectivity features, POC manufacturers must stay nimble to meet the evolving needs of millions of patients. From a financial perspective, both established leaders like Inogen and emerging disruptors like Belluscura appear well-positioned to capture significant value in a market that shows no sign of slowing down.

In short, the evolution of portable oxygen concentrators holds transformative potential—not just for patients seeking greater independence and improved respiratory health, but also for investors and healthcare systems seeking better outcomes and lower costs. As the market continues to mature, we expect consolidation and deeper collaboration across manufacturers, payers, and care providers, paving the way for next-generation devices that will define the future of oxygen therapy worldwide.

[1] https://www.openpr.com/news/3942400/respiratory-care-market-2025-size-growth-demand

[2] https://www.imarcgroup.com/portable-oxygen-concentrators-market#:~:text=Portable%20Oxygen%20Concentrators%20Market%20Size%20and%20Share:,vulnerable%20to%20chronic%20respiratory%20issues.

[3] https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd)